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ABSTRACT The presence of particular surface carbohy-
drate modifications is shown to affect dramatically the stability
and tissue specificity of unilamellar distearoyl Khosphatidyl-
choline vesicles in mice. Use of the 7-ray probe 1 In3 permits
analysis of tissue distributions by standard y counting tech-
niques and determination of the structural integrity of the ves-
icles by perturbed angular correlation spectroscopy. Addition
of a 6-aminomannose derivative of cholesterol to the lipid bi-
layer produces initial retention of high levels of intact vesicles
in the lung after intravenous injection followed by concentra-
tion of intact vesicles in the liver and spleen. Vesicles bearing
6-aminosugar residues are found to concentrate in the axillary
space in aggregates of polymorphonuclear leukocytes when
administered subcutaneously. The in vivo stability of 6-ami-
nomannose-labeled vesicles is substantially greater after in-
travenous or subcutaneous administration than that observed
for any other system examined. The dose-response effects ob-
served with surface modifications indicate that a particular
receptor topography is important in the mechanism leading to
transport and destruction of these vesicles.
The use of liposomes as carriers for delivery of therapeutic and
diagnostic agents to specific targets within the body has been
under investigation by a large number of research groups. The
complex problems encountered in in vivo therapeutic appli-
cations (1) clearly suggest the necessity to increase the specificity
of liposome targeting. To obtain satisfactory targeting of ad-
ministered agents, the liposomes must not only reach the ap-
propriate tissue but must also release their contents at the de-
sired time.
Complex carbohydrates are involved in many biological
recognition processes including antibody and toxin recognition
and cellular adhesion (2). Of particular interest are the findings
by Huang (3) and Bussian and Wriston (4) that the interaction
of glycolipid-bearing vesicles with cultured cells is carbohydrate
specific. This suggests that expansion of our previous studies
on in vwo vesicle stability (5, 6) may provide insight into the
determinants required for recognition by particular tissues. We
report here the effects of particular surface carbohydrate
modifications on lipid vesicle stability and tissue specificity in
mice. These surface modifications are achieved by incorpo-
rating carbohydrate derivatives of cholesterol into the lipid
bilayer. The use of vesicles containing high levels of II'In3+ (7)
permits analysis of tissue distributions by standard T counting
techniques and determination of the structural integrity of the
vesicles by perturbed angular correlation spectroscopy (PAC)
(5, 6). Preliminary findings (8) with this approach indicated that
vesicles with aminosugar derivatives have the greatest longevity
and a specificity for leukocytes.
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MATERIALS AND METHODS
Materials. L-a-Distearoyl phosphatidylcholine (Ste2Ptd-
Cho) from Calbiochem and cholesterol (Chol) from Sigma were
used without further purification. Fucosyl, galactosyl, man-
nosyl, acetamidogalactosyl, aminomannosyl, and aminoga-
lactosyl derivatives of cholesterol (FucChol, GalChol, ManChol,
AcAmGalChol, NManChol, and NGalChol, respectively) were
gifts from Merck, Sharp & Dohme Research Laboratories (9).
The structures of these derivatives of cholesterol are shown in
Fig. 1. Dicetyl phosphate (Cet2P) and stearylamine (NSte) were
purchased from Sigma, the trisodium salt of nitrilotriacetic acid
[N(AcOH)3] from Aldrich, ultrapure InCl3 from Ventron
(Danvers, MA), and heat-inactivated calf serum from GIBCO.
Cholesteryl [9,10-3H]oleate (specific activity, 11 Ci/g; 1 Ci =
3.7 X 1010 becquerels) and cholesteryl [1-14C]oleate (51 Ci/mol)
were obtained from New England Nuclear. Carrier-free
"'InCl3 was purchased from Medi+Physics (Glendale, CA) and
purified as described (6). The ionophore A23187 was a gift from
Eli Lilly.
Preparation of Vesicles. Unilamellar vesicles with A23187
incorporated into the bilayer were prepared as described (5,
7) by probe sonication of lipid mixtures in a buffer solution
consisting of 1 mM N(AcOH)3 in 0.9% NaCl/5 mM Na phos-
phate, pH 7.4. Vesicles of the following compositions (molar
ratio) were prepared: Ste2PtdCho/Chol/A23187, 2:1:0.004;
Ste2PtdCho/Chol/Cet2P/A23187, Ste2PtdCho/Chol/NSte/
A23187, and Ste2PtdCho/Chol/cholesterol derivative/A23187,
all 2:0.5:0.5:0.004. All preparations contained A23187; there-
fore, reference to it will be omitted hereafter in the designated
vesicle compositions. Tritiated (1 liCi) or 14C-labeled cholesteryl
oleate (0.5 MCi) were included in the mixtures as a marker for
the lipid phase.
After sonication, annealing, and low-speed centrifugation
(7, 10), the N(AcOH)3 external to the liposomes was removed
by passage of the preparation over a Sephadex G-50 column
equilibrated with phosphate-buffered saline. The vesicles were
Abbreviations: PAC, y-ray perturbed angular correlation; Ste2PtdCho,
L-a-distearoyl phosphatidylcholine; Chol, cholesterol; FucChol, Gal-
Chol, ManChol, AcAmGalChol, NGalChol, and NManChol, are fu-
cosyl, galactosyl, mannosyl, acetamidogalactosyl, aminogalactosyl,
and aminomannosyl derivatives, respectively, of cholesterol
[FucChol, 6-(1-thio-1-deoxy-f3-L-fucopyranosyl)-1-(cholest-5-en-
3/-yloxy)hexane; GalChol, 6-(1-thio-1-deoxy-f3-D-galactopy-
ranosyl)-l-(cholest-5-en-313-yloxy)hexane; ManChol, 6-(5-cholesten-
3f3-yloxyl)hexyl-l-thio-a-D-mannopyranoside; AcAmGalChol, 6-(5-
cholesten-3/3-yloxy)hexyl -2- acetamido-2-deoxy-l-thio-3- D-galac-
topyranoside; NGalChol, 6-(5-cholesten-3/3-yloxy)hexyl-6-amino-6-
deoxy-l-thio-/3-D-galactopyranoside; NManChol, 6-(5-cholesten-
3,B- yloxy)hexyl-66-amino-6-deoxy-1-thio-a-D-mannopyranoside];
N(AcOH)3, nitrilotriacetic acid; Cet2P, dicetyl phosphate; NSte,
stearylamine.
* To whom reprint requests should be addressed.
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FIG. 1. Chemical structures for the derivatives of cholesterol used
in these studies.
loaded with "'1In3+ under conditions described (5, 7) by uti-
lizing A23187 to facilitate the transport of the "'In3+ to the
chelator, N(AcOH)3, inside the vesicles.
Studies in Vivo. Vesicles containing lllIn3+ were adminis-
tered to Swiss-Webster mice (18-22 g) by intravenous (tail vein)
or subcutaneous injection (near midline of the back at the level
of the scapulae). The amount of lllIn3+ administered ranged
between 10 and 160 ,Ci per mouse depending on the type of
experiment (5). The tissue distribution of injected radioactivity
was determined by assaying all portions of the mouse in a
well-type y-ray spectrometer. All recoveries were corrected
to account for decay of the 11In3+ (t112 = 2.8 days). Typically,
4-12 mice were used for each group of time points.
To determine the residual blood content in various tissues,
the tissue distribution of lllIn3+ was measured at 8 min after
intravenous injection of radiolabeled Ste2PtdCho/Chol vesicles
(Table 1). Assuming that blood comprises 7.3% of the total
weight of the animals, we found that 89.6 ± 14.1% of the in-
jected radioactivity was in the blood. Thus, at 8 min, the vesicles
Table 1. Distribution of I11In3+ 8 min after intravenous injection
of radiolabeled Ste2PtdCho/Chol vesicles
Tissue % Tissue %
Blood* 38.9 + 4.4 Small intestine 2.5 : 0.4
Heart 1.4 + 0.5 Large intestine 0.9 1 0.2
Lung 1.3 1: 0.2 Brain 0.7 0.1
Liver 10.8 + 2.5 Abdominal tissue 8.5 i 1.6
Spleen 1.0 + 0.2 Chest tissue 10.3 + 1.2
Kidney 1.8 + 0.2 Extremities 4.7 + 0.8
Stomach 0.5 + 0.1 Skull 11.0 + 2.2
Skin 5.9 + 1.2
Reported as the mean (+SD) percentage ofrecovered radioactivity
found in each tissue. The total recovery of injected radioactivity was
102.1 + 2.7%.
* Amount of radioactivity in recovered blood and tissue wash fluid.
were still principally in the bloodstream and the distribution
of activity among the various tissues given in Table 1 represents
the blood content of the various tissues. The values in Table 1
are in good agreement with previously reported organ blood
content levels (11). All tissue distributions reported at longer
times are corrected for the activity due to residual blood con-
tent. For studies involving both intravenous and subcutaneous
administration, the distributions are given as a percentage of
the total recovered lllIn3+ because some loss may occur from
the injection site, and errors can also occur in the measurement
of the injected volumes. In all cases, blood was assumed to
comprise 7.3% of the total weight of the animal.
Autoradiograms of the skin were made in the following
manner. The pelt was carefully stretched over a flat surface,
internal side facing up. Al foil (25 ,um) was placed over the pelt
to protect the film (Kodak medical x-ray) which was sand-
wiched between the foil and a sheet containing activated ZnS
phosphor. Exposure time was approximately 15 min.
Cytological characterization of nodules was based on mi-
croscopic examination. The tissue specimens were prepared for
conventional microscopy by first embedding the sample in
paraffin; 4-Asm sections were cut, stained, for 5 min in Harris
hematoxylin/eosin reagent, and washed with water.
RESULTS
Intravenous Injection. The Ste2PtdCho/Chol/NManChol
vesicles showed substantially greater stability after intravenous
administraiqn than did the other vesicle systems tested (Fig. 2).
The corresponding tissue distributions also indicate an anom-
alous behavior for these vesicles (Table 2). In particular, Ste2-
PtdCho/Chol/NManChol vesicles cleared rapidly from the
bloodstream and showed early retention in lung tissue. At longer
times (i.e., >3 hr), the levels of 111In3+ in the liver and spleen
were significantly higher for the aminomannose-bearing ves-
icles than for other systems examined. PAC measurements on
tissue isolated 3 hr after intravenous injection of Ste2PtdCho/
Chol/NManChol vesicles showed that 97% of the vesicles in the
lungs, 97% of those in the liver, and 83% of those in the spleen
were intact. Similar studies with Ste2PtdCho/Chol vesicles
showed only 56% of those in the liver and 80% of those in the
spleen to be intact at 3 hr. At 24 hr, PAC examination of liver
showed that 55% of the vesicles in that organ were still intact
for the Ste2PtdCho/Chol/NManChol system compared with
only 18% for the Ste2PtdCho/Chol system. A positive surface
charge alone does not produce increased stability because at 12
hr with the Ste2PtdCho/Chol/NSte system only 16% of the
1lIn3+ in the liver was in intact vesicles and no intact vesicles
were found in the spleen. The substantially greater stability of
0.41 , 0oN
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FIG. 2. Stability of vesicle systems after intravenous adminis-
tration in live mice as measured by PAC. Each set of points is the
average from two mice. 0, Ste2PtdCho/Chol; A, Ste2PtdCho/Chol-
Cet2P; *, Ste2PtdCho/Chol/GalChol; 0, Ste2PtdCho/Chol/NSte; O,
Ste2PtdCho/Chol/NManChol.
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Table 2. Tissue distribution (%) of 111In3+ after intravenous injection of vesicles
Ste2PtdCho/ Ste2PtdCho/ Ste2PtdCho/ Ste2PtdCho/
Ste2PtdCho/Chol Chol/Cet2P Chol/NSte Chol/GalChol Chol/NManChol
Tissue 1 hr 3hr 24hr 3hr 24hr 3hr 24hr 3hr 24hr 1 hr 3hr 24hr
Blood 85.5 54.4 6.0 38.4 6.5 28.1 5.9 38.2 2.0 2.1 1.0 0.3
+0.6 +9.3 +2.9 -i4.9 ±2.1 ±7.1 4-1.7 ±6.5 ±1.8 :0.5 ±0.2 ±0.1
Heart 0.1 0.4 0.4 0.2 0.4 0.1 0.4 0.1 0.4 0.8 0.1 0.1
Lung 0.7 1.9 1.3 0.8 0.5 1.5 0.5 1.0 0.6 24.0 5.9 1.2
4-0.3 +1.2 -+1.0 4-0.2 4-0.1 +:0.7 ±0.1 10.6 :0.2 ±-5.2 ±3.8 +0.4
Liver 3.3 14.5 30.4 12.9 20.6 50.6 51.5 13.9 37.2 31.6 66.8 65.8
±0.1 +-2.7 ±9.9 14.3 :t3.5 -+2.9 -i6.2 4-1.6 4-8.8 4-3.8 ±8.3 4-1.0
Spleen 0.6 1.8 4.1 2.8 1.9 3.0 2.3 1.1 2.4 3.5 7.4 8.5
Kidney 1.2 1.9 2.7 2.5 4.3 1.1 1.9 2.1 4.2 4.6 1.8 1.8
Stomach 0.2 0.4 0.9 0.3 1.4 0.3 0.5 0.3 0.7 0.7 0.2 0.2
Small int. 2.5 6.1 10.9 7.2 14.2 3.8 4.8 7.5 10.5 5.0 1.6 1.2
Large int. 0.4 2.1 3.9 3.1 4.4 1.1 1.3 2.5 3.7 1.7 0.8 0.8
Brain * 0.1 * 0.1 * * * 0.1 * 0.2 * *
Abd. & chest 3.3 7.6 14.6 13.8 17.9 4.9 11.6 13.5 16.4 13.6 6.7 9.9
Extremities 2.1 3.1 8.8 5.8 7.4 2.1 9.1 7.0 7.3 3.2 3.4 5.4
Skull * 1.8 5.3 3.3 7.3 0.3 3.6 3.1 5.0 3.7 1.8 2.7
Skin * 3.8 10.7 8.8 13.2 3.1 6.6 9.6 9.7 5.4 2.6 2.2
% recovered:
Injected dose 99 98 104 98 100 95 96 101 100 102 104 106
Blood 40.8 38.6 41.7 41.9 30.8 24.9 50.8 35.6 25.0 33.3 40.0 44.1
All values were corrected for the radioactivity in tissue blood; blood was assumed to comprise 7.3% of the total weight of the animal. Values
for blood, lung, and liver include + SD.
* Value less than 0.1%.
the aminomannose-bearing vesicles observed in these tissues
accounts for the overall increased longevity observed in live
animals with this system (Fig. 2).
Subcutaneous Injection. Distributions of radioactivity
among various tissues following subcutaneous injection are
shown in Table 3 for various different vesicle compositions. For
the first 12 hr after subcutaneous injection, the tissue distribu-
tions for all vesicle systems examined were similar (Table 3).
However, at long times (e.g., >72 hr), some differences in the
tissue distributions were apparent. In particular, the amino-
mannose-bearing vesicles showed a higher level of 1llIn3+ in
the skin than observed with the other vesicle systems, whereas
the fraction retained in the liver appeared to increase for the
non-aminomannose systems. It is of interest that the amino-
mannose vesicle system which retained a high fraction of ac-
tivity in the skin at long times is also the system-shown previ-
ously (8) to have an extremely long half-time for vesicle de-
struction (i.e., 600 hr) after subcutaneous injection.
Within 1 hr after subcutaneous injection of vesicles bearing
the aminosugar derivatives of cholesterol, a moist appearing,
blister-like structure could be seen with the unaided eye. The
swelling has been observed up to 8 hr after injection. With
Table 3. Tissue distribution (%) of recovered lllIn3+ after subcutaneous injection of vesicles
Ste2- Ste2- Ste2- Ste2- Ste2-
PtdCho/Chol PtdCho/Chol/Cet2P PtdCho/CholINSte PtdCho/Chol/GalChol PtdCho/Chol/NManChol
0-24 24-72 >72 0-12 12-24 24-72 >72 0-24 24-72 >72 0-24 24-72 >72 0-24 24-72 72-240 >240
Tissue hr hr hr hr hr hr hr hr hr hr hr hr hr hr hr hr hr
1.0 0.2 0.2 1.5 1.7 0.3 0.1 0.5 0.4 0.5 0.8 0.2 0.1 2.1 0.2 0.09 0.2
0.03 0.05 0.06 0.03 0.07 0.06 0.1 * 0.02 0.06 0.03 0.03 0.04 0.05 0.02 0.04 0.04
0.1 0.2 0.2 0.1 0.3 0.1 0.4 0.02 0.05 0.1 0.04 0.04 0.06 0.08 0.03 0.06 0.06
2.4 3.5 8.7 1.8 7.7 7.1 11.9 0.3 1.6 4.0 2.2 4.5 6.1 1.3 2.1 2.8 2.4
0.1 0.2 0.6 0.3 0.9 0.6 1.5 0.1 0.1 0.3 0.07 0.2 0.2 0.1 0.2 0.1 0.1
0.2 0.6 0.8 0.3 0.7 0.8 0.9 0.2 0.8 1.2 0.3 0.5 0.6 0.5 0.6 0.6 0.6
0.1 0.1 0.1 1.2 0.2 0.2 0.2 0.9 0.1 0.2 0.06 0.09 0.1 0.2 0.09 0.2 0.08
0.8 1.0 1.5 1.2 2.6 2.2 2.5 0.5 0.9 1.1 0.7 1.1 1.0 1.2 0.7 0.3 0.5
0.6 0.4 0.7 0.5 1.1 0.9 1.2 0.8 0.5 0.9 0.5 0.5 0.4 0.8 0.5 0.2 0.3
* * * * 0.02 * 0.02 * * 0.02 * * * * 0.02 0.03 0.02
17.5 18.8 18.3 16.7 20.6 18.7 21.9 18.1 19.4 19.2 19.9 20.8 22.3 15.2 13.6 12.6 16.5
0.5 1.6 1.6 3.3 2.4 4.6 4.4 0.5 0.8 1.2 0.7 1.7 1.5 1.1 0.8 1.0 1.1
0.5 0.9 1.0 0.5 1.8 1.5 1.9 0.3 0.7 1.4 0.7 1.6 1.6 0.6 0.8 1.0 0.9
76.2 72.6 66.4 72.6 60.1 63.1 53.0 78.0 74.7 69.8 \73.9 68.9 66.0 76.9 80.3 81.1 77.3
18.3 4-3.4 ±4.0 -18.7 +4.7 ±6.3 +5.6 +14.1 ±11.4 17.2S ±5.5 43.2 19.2 16.6 +15.6 110.0 +10.2
% injected dose
recovered 97 99 104 96 98 101 95 ND ND 102 100 102 90
All values were corrected for the radioactivity in tissue blood. ND, not determined.
* Values less than 0.02%.
t Values for skin include ± SD.
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FIG. 3. Autoradiographic evidence for the localization of vesicles.
An autoradiogram of the skin was prepared and the portion coinciding
with the bleb is shown here.
multilamellar vesicles bearing the aminomannose derivative,
the localized swelling persisted up to 22 hr after subcutaneous
administration.
The blebs coincided with the location of the II'In3+ (Fig. 3).
The pattern observed in the autoradiogram shows that the bleb
does not represent intact migration of the injection bolus. The
radioactivity appeared confined within a fibrous structure. The
bleb was examined on 4-.um-thick tissue sections by using a
phase-contrast procedure and was found to be comprised of
aggregates of polymorphonuclear leukocytes (Fig. 4).
From the specific activity of the skin tissue, it was apparent
that the Ste2PtdCho/Chol/NManChol vesicles were severalfold
more concentrated in the skin than were vesicles of other
compositions-for example, Ste2PtdCho/Chol/GalChol ves-
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FIG. 4. Bleb structure. The blisters are formed of channels be-
tween the deep fascia and the muscle layer of subcutaneous tissue
containing large numbers of polymorphonuclear leukocytes.
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FIG. 5. PAC evidence for the localization of aminosugar-bearing
vesicles after subcutaneous injection. 0, Ste2PtdCho/Chol/NMan-
Chol, 2:0.5:0.5 (molar ratio); O, Ste2PtdCho/Chol/NGalChol, 2:0.5:0.5;
A, SteiPtdCho/Chol/NManChol, 2:0.75:0.25.
icles. Because the PAC results must be corrected for the finite
geometry of the radioactive samples analyzed, the observed
(G22(w)) values can be used as an additional means of esti-
mating the concentration of these vesicles. For the aminosu-
gar-bearing vesicles, the (G22(oo)) values on portions of the skin
containing radioactivity showed an initial decline not observed
with other vesicle systems (Fig. 5). The effective sample volume
at these times can be estimated from standard geometric cor-
rections for the PAC spectrometer. For example, reduction of
sample size from a sphere of 200 Al to a sphere of 75 MAl results
in a 25% reduction in the apparent (G22(w)) value. As indicated
in Fig. 5, a 50% reduction in the amount of NManChol deriv-
ative in the vesicle bilayer substantially reduced this geometric
effect and also reduced the in vivo vesicle stability.
DISCUSSION
Modification of the surface characteristics of lipid vesicles
through incorporation into the bilayer of various derivatives
of cholesterol has been shown to alter markedly the in vtvo
stability and tissue specificity of the vesicles. Of the derivatives
studied, those with a primary amine group at C-6 of the sugar
moiety showed the most enhanced stability. When administered
subcutaneously, in vivo half-times of 100 and 600 hr were found
for the aminogalactose and aminomannose systems, respec-
tively, compared to a half-time of 21 hr for the control
Ste2PtdCho/Chol systems (8). This is a much greater en-
hancement than anticipated from findings with unsubstituted
sugar derivatives or with NSte incorporated into the bilayer.
The effects observed with the aminosugar derivatives may be
attributed to the stereochemical positioning of the amino group
at C-6. This amine should be highly exposed on the vesicle
surface. The differences in in vivo stability between the ami-
nogalactose- and aminomannose-bearing vesicles -may arise
from two types of stereochemical changes. One of these is a
structural difference at the anomeric carbon. The galactose
derivatives used here were 3 isomers; the mannose derivatives
were a isomers. The other type of change is epimerizations at
C-2 and C-4. With the derivatives available, the relative effects
of these two types of changes cannot yet be evaluated.
The population of amine groups on the vesicle surface also
is an important factor in vesicle behavior. A 50% reduction in
the amount of aminomannose derivative (i.e., Ste2PtdCho/
Chol/NManChol at 2:0.75:0.25) caused a substantial reduction
in the extent of localization and a marked decrease in in vivo
vesicle stability. As reported (8), when the level of amino-
mannose is lowered still further (i.e., Ste2PtdCho/Chol/
NManChol at 2:0.9:0.1), no bleb formation is observed in the
Biochemistry: Mauk et al.
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axillary space. This suggests that a certain concentration of
groups on the vesicle surface is required to produce the lon-
gevity and tissue specificity observed. Such a dose-response
effect is not unique. For example, in studying model systems
for cell-cell agglutination, Curatolo et al. (12) found that ves-
icles must contain at least 5 mol % of the glycolipid lactosyl-
ceramide to be agglutinated by a plant lectin. At higher gly-
colipid contents, agglutination increased with increasing gly-
colipid content.
The anomalous behavior exhibited by vesicles bearing ami-
nosugar derivatives of cholesterol suggests that a particular
receptor topography is important in the mechanism leading to
transport and destruction of these vesicles. After subcutaneous
injections, these vesicles do not remain at the site of injection
but are found in blebs in the axillary space. The blebs are filled
with aggregates of polymorphonuclear leukocytes. The detailed
explanation for these effects must include steps such as the
recognition of the aminosugar receptor analogues, the pro-
duction of a chemotactic factor to attract the leukocytes, the
transport of the vesicles along with the leukocytes to the axillary
space, and the eventual destruction of the vesicles.
Information on whether similar steps are involved in the
processing of aminosugat-bearing vesicles when they are in-
jected intravenously is obtained from tissue distribution data
for aminomannose-bearing vesicles. With this vesicle system,
a pattern of rapid clearance from the blood with early deposi-
tion in the lungs and then subsequent accumulation in liver and
spleen is observed. Comparison of these data with patterns
observed after intravenous administration of "'lIn-oxine-labeled
wleukocytes (13, 14) reveals little similarity. However, our data
bear a marked resemblance to tissue distributions observed after
administration of "1'In-oxine-labeled heat-damaged leukocytes
in both rats (13) and rabbits (15). Thus our intravenous results
suggest that, after recognition, the aminomannose vesicles could
interact with similar cell types, causing these cells to undergo
a change (e.g., in surface markers) that leads to these cells being
earmarked for destruction. The aminomannose vesicles might
remain with the cell, with the vesicles existing intact for ex-
tended periods, and hence would exhibit the tissue distribution
observed for heat-killed cells.
Our approach of systematically investigating surface groups
on lipid vesicles is directed at identifying modifications that will
allow the vesicles to be recognized by specific tissues. Various
other approaches including use of specific antibodies (16) and
receptor-bearing particles (17) have been tried in attempts to
achieve targeting. Our experimental results with carbohydrates
as phospholipid vesicle surface modifications are consistent with
the growing body of information implicating glycolipids as cell
surface receptors (2, 12, 18). Our findings indicate that further
study of mechanisms of recognition and transport of amino-
sugar-labeled vesicles in evo and examination of additional
carbohydrate derivatives could provide a major advance toward
achieving targeting and controlled release of vesicle con-
tents.
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